Merck & Co Inc

NYSE:MRK  
78.27
-0.42 (-0.53%)
4:00:00 PM EDT: $78.24 -0.03 (-0.04%)
Earnings Announcements

Merck And Eisai Present First-Time Data From Two Studies Evaluating Keytruda Plus Lenvima In Seven Different Tumor Types At ESMO

Published: 09/20/2020 12:59 GMT
Merck & Co Inc (MRK) - Merck and Eisai Present First-time Data From Two Studies Evaluating Keytruda® (pembrolizumab) Plus Lenvima® (lenvatinib) in Seven Different Tumor Types at Esmo Virtual Congress 2020.
Merck & Co Inc - Findings From Phase 2 Leap-004 Trial Showing Orr of 21.4% in Patients With Unresectable Or Advanced Melanoma.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.